Pharmaceuticals News and Research

RSS

French Ministry of Research grants French R&D tax credit accreditation to Cyprotex

Cyprotex, the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

Covidien's second-quarter medical devices sales up 11%

Covidien plc today reported results for the second quarter of fiscal 2010 (January - March 2010).

21 Apr 2010

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Drugmakers raised prices last year in anticipation of new health law, Eli Lilly reports financial hit

"Drug companies sharply raised prices last year, ahead of increased rebates they must pay to Medicaid and other expenses tied to the federal health overhaul passed last month. Prices for brand-name pharmaceuticals rose 9.1% last year, the biggest increase in at least a decade, according to pharmacy-benefit manager Express Scripts Inc."

21 Apr 2010

CVS Caremark survey results of specialty pharmacy patients

CVS Caremark today announced results of a survey of the company's specialty pharmacy patients that provides insights into their views on medication adherence and their perceptions about the role of their specialty pharmacy. The survey results show nearly 70 percent of respondents believe their specialty pharmacy team played an important role in encouraging them to take their specialty medications as prescribed.

21 Apr 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

21 Apr 2010

Researchers discover subunits of GABAB receptors in central nervous system

In the latest issue of the renowned scientific journal "Nature" researchers from the universities of Freiburg and Basel report on their discovery of previously unknown subunits of the GABAB receptors in the central nervous system. GABAB receptors are transmembrane proteins in nerve cells which are of fundamental significance for the functioning of the brain and have great therapeutical and pharmaceutical importance.

21 Apr 2010

Simcyp wins Queen's Award for Enterprise for innovative research and development

Simcyp Limited, experts in simulating how the body deals with new drugs in development, today announces that it has won a Queen's Award for Enterprise. The award has been made in the Innovation category and reflects Simcyp's continuous development of modelling and simulation software for evaluating drugs in the safety of a computer.

21 Apr 2010

Unwarranted increase in use of psychotropic medications for children

A new study from the Journal of Marital & Family Therapy warns of the dramatic rise in the use of psychotropic medications for children. One in every fifty Americans is now considered permanently disabled by mental illness, and up to eight million children take one or more psychotropic drugs.

21 Apr 2010

UK scientists find new drug for women with inherited form of ovarian cancer

A team of UK scientists, part-funded by Cancer Research UK, have found that a new type of drug could help women with an inherited form of ovarian cancer.

21 Apr 2010

Proteus Biomedical's wireless personal health device receives FDA marketing clearance

Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that it has received 510(k) clearance from the US Food and Drug Administration to market its wireless personal health device, the Raisin Personal Monitor.

21 Apr 2010

Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand

Ligand Pharmaceuticals Incorporated today announced that it earned a $6.5 million payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc.

21 Apr 2010

Lipocine announced receipt of $2M development milestone payment from Abbott

Lipocine Inc. announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone.

21 Apr 2010

Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China reported that its asthma drug Laevo-Bambutero will receive the China's State Food & Drug Administration's (SFDA) Fast Track Approval to enter clinical trials. The SFDA's Drug Review and Evaluation Center told the Company during recent consultations at the end of the Company's IND that formal approval would be granted by the Beijing office of the SFDA.

21 Apr 2010

Elan's first-quarter total revenue up by 27% to $310.5M

Elan Corporation, plc, today reported its first quarter 2010 financial results.

21 Apr 2010

Gemin X Pharmaceuticals closes $16 million Series D financing

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.

21 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

Pharmaceuticals News and Research

French Ministry of Research grants French R&D tax credit accreditation to Cyprotex

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Covidien's second-quarter medical devices sales up 11%

Ajinomoto AminoScience introduces new resource for peptides

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Drugmakers raised prices last year in anticipation of new health law, Eli Lilly reports financial hit

CVS Caremark survey results of specialty pharmacy patients

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Researchers discover subunits of GABAB receptors in central nervous system

Simcyp wins Queen's Award for Enterprise for innovative research and development

Unwarranted increase in use of psychotropic medications for children

UK scientists find new drug for women with inherited form of ovarian cancer

Proteus Biomedical's wireless personal health device receives FDA marketing clearance

Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand

Lipocine announced receipt of $2M development milestone payment from Abbott

Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval

Elan's first-quarter total revenue up by 27% to $310.5M

Gemin X Pharmaceuticals closes $16 million Series D financing

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence